Aston Sci. Inc., a clinical-stage biopharmaceutical company focused on advancing next-generation therapeutic cancer vaccines, has announced the adoption of CDD Vault®, a secure, cloud-based research informatics solution developed by Collaborative Drug Discovery (CDD). The platform will support Aston Sci.’s growing research initiatives powered by its proprietary Th-Vac® epitope discovery platform, which is strengthened by the Antigen Structure-Based Epitope Prediction (ASEP) program.
Through Th-Vac®, Aston Sci. is developing mRNA-, DNA-, and peptide-based cancer vaccines using an AI-driven in silico epitope prediction approach combined with targeted immunological screening. This strategy enables the identification of MHC class II–restricted epitopes capable of inducing strong and long-lasting CD4⁺ T-cell immune responses. By integrating multi-omics data with machine-learning technologies, the platform addresses key challenges in cancer vaccine development, including tumor heterogeneity, extended manufacturing timelines, and limitations in patient coverage.
As research activities and collaboration efforts continue to expand, CDD Vault will provide a centralized and secure environment for managing biological data, enhancing workflow efficiency, and enabling seamless collaboration with both internal teams and external research partners.
